Last reviewed · How we verify
biphasic human insulin 30
biphasic human insulin 30 is a Insulin (premixed biphasic formulation) Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biphasic human insulin 30 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin (premixed biphasic formulation) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This formulation contains 30% soluble (rapid-acting) human insulin and 70% isophane (intermediate-acting) human insulin, allowing for a single injection that provides both immediate postprandial glucose control and basal insulin coverage. The rapid-acting component addresses mealtime glucose spikes, while the intermediate-acting component provides sustained glucose control between meals and overnight.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure (PHASE2)
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Embryo Developmental Potential in a Novel 2-step IVM System (NA)
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) Study (PHASE4)
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biphasic human insulin 30 CI brief — competitive landscape report
- biphasic human insulin 30 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about biphasic human insulin 30
What is biphasic human insulin 30?
How does biphasic human insulin 30 work?
What is biphasic human insulin 30 used for?
Who makes biphasic human insulin 30?
What drug class is biphasic human insulin 30 in?
What development phase is biphasic human insulin 30 in?
What are the side effects of biphasic human insulin 30?
What does biphasic human insulin 30 target?
Related
- Drug class: All Insulin (premixed biphasic formulation) drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Compare: biphasic human insulin 30 vs similar drugs
- Pricing: biphasic human insulin 30 cost, discount & access